BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 20225905)

  • 1. Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg in young women: results of the prospective, observational, non-interventional, multicentre TeeNIS study.
    Anthuber S; Schramm GA; Heskamp ML
    Clin Drug Investig; 2010; 30(4):211-20. PubMed ID: 20225905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen.
    Brucker C; Hedon B; The HS; Höschen K; Binder N; Christoph A
    Contraception; 2010 Jun; 81(6):501-9. PubMed ID: 20472117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety data and beneficial effects of the combined oral contraceptive ethinylestradiol 0.03 mg/chlormadinone acetate 2 mg (Belara®): a 13-cycle, observational study in routine clinical practice.
    Pushparajah DS; Röhm P; Höschen K; Albers D; Nowack C
    Clin Drug Investig; 2011; 31(2):121-34. PubMed ID: 21155614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study.
    Schramm G; Heckes B
    Contraception; 2007 Aug; 76(2):84-90. PubMed ID: 17656175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of efficacy, safety and effects on symptoms of androgenization of a generic oral contraceptive containing chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg.
    Hadji P; Biskup J; Boekhoff J; Ziller M; Bonn M; Rovati L
    Contraception; 2012 Oct; 86(4):359-65. PubMed ID: 22445436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of an oral contraceptive containing chlormadinone acetate: results of a pooled analysis of noninterventional trials in adult and adolescent women.
    Schramm GA; Schrah G
    Contraception; 2011 Oct; 84(4):390-401. PubMed ID: 21920195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the low-dose combined oral contraceptive chlormadinone acetate/ethinylestradiol: physical and emotional benefits.
    Heskamp ML; Schramm GA
    Contraception; 2010 Jan; 81(1):49-56. PubMed ID: 20004273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended cycles with the combined oral contraceptive chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg: pooled analysis of data from three large-scale, non-interventional, observational studies.
    Göretzlehner G; Waldmann-Rex S; Schramm GA
    Clin Drug Investig; 2011; 31(4):269-77. PubMed ID: 21250761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial.
    Plewig G; Cunliffe WJ; Binder N; Höschen K
    Contraception; 2009 Jul; 80(1):25-33. PubMed ID: 19501212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral contraceptives containing estradiol and nomegestrol acetate or ethinyl-estradiol and chlormadinone acetate on primary dysmenorrhea.
    Grandi G; Napolitano A; Xholli A; Tirelli A; Di Carlo C; Cagnacci A
    Gynecol Endocrinol; 2015 Oct; 31(10):774-8. PubMed ID: 26291811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethinylestradiol/chlormadinone acetate.
    Curran MP; Wagstaff AJ
    Drugs; 2004; 64(7):751-60; discussion 761-2. PubMed ID: 15025547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon).
    Worret I; Arp W; Zahradnik HP; Andreas JO; Binder N
    Dermatology; 2001; 203(1):38-44. PubMed ID: 11549798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups: an open-label, single-centre, phase IV study.
    Kerscher M; Reuther T; Bayrhammer J; Schramm G
    Clin Drug Investig; 2008; 28(11):703-11. PubMed ID: 18840013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the new antiandrogenic oral contraceptive Belara.
    Zahradnik HP; Goldberg J; Andreas JO
    Contraception; 1998 Feb; 57(2):103-9. PubMed ID: 9589837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethinylestradiol/Chlormadinone acetate: dermatological benefits.
    Guerra-Tapia A; Sancho Pérez B
    Am J Clin Dermatol; 2011 Sep; 12 Suppl 1(Suppl 1):3-11. PubMed ID: 21895044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belara--a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea.
    Zahradnik HP
    Eur J Contracept Reprod Health Care; 2005; 10 Suppl 1():12-8. PubMed ID: 16356877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R; Orrù M; Pani F; Marotto MF; Pilloni M; Guerriero S; Etzi R; Zedda P; Sorge R; Lello S; Melis GB; Paoletti AM
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
    Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
    Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.